Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 161Tb-RAD402 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on 161Tb-RAD402, a putative radioconjugate comprising a monoclonal antibody targeting KLK3 linked to terbium-161 (Jul 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 161Tb-RAD402 | [161Tb]Tb-RAD402|161Tb RAD402|161Tb-RAD-402 | Limited information is currently available on 161Tb-RAD402, a putative radioconjugate comprising a monoclonal antibody targeting KLK3 linked to terbium-161 (Jul 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07259213 | Phase Ib/II | 161Tb-RAD402 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC (RAD402) | Recruiting | AUS | 0 |